SCHEMBL307301

SCHEMBL307301

CC(=O)Nc1nc(CCl)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 1.00
KMT2A Q03164 1/20 1.00
AOC3 Q16853 7/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
CASP3 P42574 1/20 0.52
HTT P42858 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
ABL1 P00519 3/20 0.51
CDK5 Q00535 3/20 0.51
CDK5R1 Q15078 3/20 0.51
MAOB P27338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9834676 0.87 SMN1; SMN2 (0.77) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL3933173 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL353851 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2ANPC1RAB9AKDM4E
SCHEMBL2612387 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL9836892 0.84 SMN1; SMN2 (0.72) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL9677782 0.83 SMN1; SMN2 (0.71) SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1
SCHEMBL9835719 0.83 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL11202231 0.83 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL4068199 0.83 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL17977308 0.83 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 CN disclosed
US-11224224-B2 Thiobenzoimidazole as fungicides REDAG CROP PROTECTION LTD. (GB) 2022-01-18 US disclosed
US-11046644-B2 Sulfur derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2021-06-29 US disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-20200109110-A1 SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-04-09 US disclosed
US-20200085053-A1 THIOBENZOIMIDAZOLE AS FUNGICIDES REDAG CROP PROT LTD (GB) 2020-03-19 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
US-10287243-B2 Sulfur derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2019-05-14 US disclosed
US-4742060-A 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1988-05-03 US disclosed
US-4742057-A Antiallergic thiazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-05-03 US disclosed
EP-0224919-A2 New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-06-10 EP disclosed
EP-0192060-A1 Heterocyclic compounds NIHON BAYER AGROCHEM K.K. (JP) 1986-08-27 EP disclosed
EP-0032058-B1 THIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-10-26 EP disclosed
US-4411900-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-10-25 US disclosed
EP-0032131-B1 5-HALO-PYRIMIDIN-2-ONES, THE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NYEGAARD & CO. A/S (NO) 1983-09-21 EP disclosed
US-4399140-A CYTOTOXIC NYEGAARD & CO. A/S (NO) 1983-08-16 US disclosed
EP-0032131-A1 5-Halo-pyrimidin-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them NYEGAARD & CO. A/S (NO) 1981-07-15 EP disclosed
EP-0032058-A1 Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11224224-B2 Thiobenzoimidazole as fungicides CYP1B1, CYP51A1, CYP1A2 SMN1; SMN2 3466/4885KMT2A 2065/4885AOC3 348/4885
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B SMN1; SMN2 805/4885KMT2A 121/4885AOC3 3904/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B SMN1; SMN2 805/4885KMT2A 121/4885AOC3 3904/4885
US-20200109110-A1 SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CX3CR1, CXCR2, CCR2 SMN1; SMN2 4664/4885KMT2A 4835/4885AOC3 4179/4885
US-10287243-B2 Sulfur derivatives as chemokine receptor modulators CX3CR1, CXCR2, CCR2 SMN1; SMN2 4664/4885KMT2A 4835/4885AOC3 4179/4885
US-11046644-B2 Sulfur derivatives as chemokine receptor modulators CX3CR1, CXCR2, CCR2 SMN1; SMN2 4664/4885KMT2A 4835/4885AOC3 4179/4885
US-20200085053-A1 THIOBENZOIMIDAZOLE AS FUNGICIDES CYP1B1, CYP51A1, CYP1A2 SMN1; SMN2 3466/4885KMT2A 2065/4885AOC3 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.